GoalVest Advisory LLC Grows Position in Amgen Inc. (NASDAQ:AMGN)

GoalVest Advisory LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 215.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 537 shares of the medical research company’s stock after acquiring an additional 367 shares during the quarter. GoalVest Advisory LLC’s holdings in Amgen were worth $153,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of AMGN. Sovereign Financial Group Inc. grew its holdings in Amgen by 11.0% in the first quarter. Sovereign Financial Group Inc. now owns 1,451 shares of the medical research company’s stock valued at $413,000 after purchasing an additional 144 shares during the last quarter. Elevated Capital Advisors LLC boosted its stake in shares of Amgen by 8.0% during the first quarter. Elevated Capital Advisors LLC now owns 1,328 shares of the medical research company’s stock valued at $378,000 after acquiring an additional 98 shares during the last quarter. Constitution Capital LLC acquired a new stake in shares of Amgen during the first quarter valued at $218,000. Chemistry Wealth Management LLC boosted its stake in shares of Amgen by 20.0% during the first quarter. Chemistry Wealth Management LLC now owns 3,443 shares of the medical research company’s stock valued at $979,000 after acquiring an additional 573 shares during the last quarter. Finally, IAM Advisory LLC boosted its stake in shares of Amgen by 2.0% during the first quarter. IAM Advisory LLC now owns 6,919 shares of the medical research company’s stock valued at $1,967,000 after acquiring an additional 138 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares in the company, valued at approximately $3,094,268.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on AMGN shares. Truist Financial reaffirmed a “buy” rating and set a $320.00 price objective on shares of Amgen in a research note on Friday, April 12th. UBS Group increased their target price on Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Raymond James assumed coverage on Amgen in a research report on Thursday, March 28th. They set a “market perform” rating on the stock. Morgan Stanley increased their target price on Amgen from $271.00 to $310.00 and gave the stock an “equal weight” rating in a research report on Friday, May 3rd. Finally, StockNews.com upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Ten analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $307.35.

Amgen Price Performance

Shares of AMGN opened at $313.69 on Friday. The firm has a market cap of $168.27 billion, a price-to-earnings ratio of 44.81, a PEG ratio of 2.88 and a beta of 0.60. The stock has a 50 day moving average of $299.67 and a 200-day moving average of $291.67. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. Amgen Inc. has a 52 week low of $218.44 and a 52 week high of $329.72.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping the consensus estimate of $3.76 by $0.20. The company had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The business’s revenue was up 22.0% on a year-over-year basis. During the same quarter last year, the firm earned $3.98 EPS. As a group, analysts forecast that Amgen Inc. will post 19.47 EPS for the current year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.